Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
Public ClinicalTrials.gov record NCT03956225. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
Study identification
- NCT ID
- NCT03956225
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 299 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2019 (Actual)
- Primary completion
- Oct 24, 2020 (Actual)
- Completion
- Oct 24, 2020 (Actual)
- Last update posted
- Oct 8, 2021
2019 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alcon Investigator 9083 | Long Beach | California | 90815 | — |
| Alcon Investigator 9081 | Los Angeles | California | 90013 | — |
| Alcon Investigator 9084 | San Diego | California | 92122 | — |
| Alcon Investigator 5127 | Panama City | Florida | 32405 | — |
| Alcon Investigator 4782 | Highland Park | Illinois | 60035 | — |
| Alcon Investigator 6567 | Pittsburg | Kansas | 66762 | — |
| Alcon Investigator 5582 | Louisville | Kentucky | 40206 | — |
| Alcon Investigator 6402 | Medina | Minnesota | 55340 | — |
| Alcon Investigator 1455 | Kansas City | Missouri | 64111 | — |
| Alcon Investigator 3828 | Poughkeepsie | New York | 12603 | — |
| Alcon Investigator 8046 | Granville | Ohio | 43023 | — |
| Alcon Investigator 6313 | Powell | Ohio | 43065 | — |
| Alcon Investigator 9082 | Chambersburg | Pennsylvania | 17201 | — |
| Alcon Investigator 8028 | Wichita Falls | Texas | 76308 | — |
| Alcon Investigator 5163 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03956225, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2021 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03956225 live on ClinicalTrials.gov.